论文部分内容阅读
目的:观察泰索帝联合吡柔比星治疗晚期乳腺癌临床疗效及不良反应。方法:26例均有组织病理学或细胞学诊断及可评价客观指标。采用泰索帝75mg/m2d1,静脉滴注1小时,用泰索帝前1天口服地塞米松10mg,连续3天。吡柔比星40mg/m2d2化疗。21天为1周期,2个周期评价疗效。结果:26例可评价疗效和不良反应。CR3例,PR16例,NC5例,PD2例,有效率73.1%。不良反应主要为白细胞减少Ⅲ度占34.6%,Ⅳ度占26.9%,脱发Ⅱ度占46.2%,Ⅲ度占23.1%,腹泻Ⅱ度占34.6%,Ⅲ度占23.1%。结论:泰索帝联合吡柔比星治疗晚期乳腺癌有效率较高,不良反应可以耐受。
Objective: To observe the clinical efficacy and adverse reactions of taxotere combined with pirarubicin in the treatment of advanced breast cancer. Methods: Twenty-six cases had histopathological or cytological diagnosis and objective evaluation. Taxotere 75mg / m2d1, intravenous infusion of 1 hour, 1 day before using Taxotere oral dexamethasone 10mg, for 3 days. Pirarubicin 40mg / m2d2 chemotherapy. 21 days for 1 cycle, 2 cycles evaluation of efficacy. Results: 26 cases could evaluate the curative effect and adverse reaction. CR3 cases, PR16 cases, NC5 cases, PD2 cases, the effective rate was 73.1%. The main adverse reactions were leukopenia Ⅲ degree 34.6%, Ⅳ degree 26.9%, hair loss Ⅱ degree 46.2%, Ⅲ degree 23.1%, diarrhea Ⅱ degree 34.6% and Ⅲ degree 23.1%. Conclusion: Taxotere combined with pirarubicin in the treatment of advanced breast cancer is more effective, adverse reactions can be tolerated.